contact
about us services facilities chemistry Quality Case Studies news employment employment

Executive Team
Michael W. Major, Ph.D., D.Sc.
    President and CEO
Brian Scanlan
    Chief Business Officer
Mark Abatto
    Chief Financial Officer
John Zobel
    VP of Operations
Alexander Tretyakov, Ph.D.
    VP - R&D

Management Team
Keith Drouet, Ph.D.
    Sr. Director Business Development
Gary Masse, Ph.D.
    Director of Manufacturing
Dan Su, Ph.D.
    Manager, Analytical Services
Bob Beffa
    Director Q.A./Regulatory Compliance
Lois LeBrasseur
    Manager of Human Resources

Peter Van Tilburg
    President
Erwin Warmerdam, Ph.D.
    Director of Operations
Bernd Vergouwen
    Director of Medicinal Chemistry
Roger Mcdonald
    Director Business Development Europe
Chris Tournelle
    Plant Manager
Marie-José Vullers
    Q.A. Manager

 


Alexander Tretyakov, Ph.D.

Vice President - R&D

Alexander TretyakovDr. Alexander Tretyakov brings over 23 years of experience spanning a diverse range of organic chemistries.  His background includes organometallic and chiral chemistries, de-novo route design, development of new chemical technologies and scale up from laboratory to plant scale.  He is responsible for directing all of CML’s R&D and process development personnel; mostly Ph.D. level scientists.


Prior to joining CML he formed the startup company, Omega Engineering, providing custom synthesis solutions to the pharma and fine chemical industries. Before that he worked in various roles in chemical engineering, R&D, and plant management.

 

He earned his Ph.D. in organic chemistry from the University of Oklahoma, where he studied new strategies for the synthesis of Cyclopentadienyl and Indenyl Metallocene Dichloride Complexes. He also devised and synthesized new classes of bridged bisindenyl ligands used in chiral synthesis. He earned his Masters Degree in Chemical Engineering from the Leningrad Chemical-Pharmaceutical Institute, Leningrad, Russia, where he studied various six-membered heterocyclic compounds with potential antitumor activity using the [3+3] and [4+2] cycloaddition reactions.

   

Home | About Us | Services | Facilities | Chemistry | Quality | Case Studies | News | Employment | Contact
Cambridge Major Laboratories, Inc. | W130 N10497 Washington Drive | Germantown, WI 53022 | 262-251-5044 | Fax 262-251-5577